
Combination Therapies: The Next Step in Slowing Type 1 Diabetes
Experts say that combining multiple immune-modulating drugs with different mechanisms may be needed to better preserve insulin-producing beta cells and control Type 1 diabetes long-term. One drug approved so far, teplizumab, slows beta cell decline but is not a standalone solution.
Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.
Key takeaways
- Teplizumab (Tzield) is currently the only FDA-approved drug to delay Type 1 diabetes onset in certain stages, but it works best as part of a broader treatment strategy, not alone.
- Combination therapies using drugs that work differently—targeting immune tolerance, beta cell protection, and other pathways—represent the likely next frontier in disease management.
- Early disease stages may offer a better window for immune-modulating therapies to work, while later stages may require different approaches like beta cell replacement.
- Beyond medication, lifestyle factors, screening for autoantibodies, and psychosocial support play important roles in managing Type 1 diabetes risk.
- The microbiome appears to influence Type 1 diabetes development, opening new research avenues for microbiota-targeted therapies in the future.
One Drug Isn't Enough: Why Combination Therapy Matters
For the first time, the FDA approved a drug specifically designed to slow the progression of Type 1 diabetes: teplizumab (Tzield), a monoclonal antibody that modulates the immune system. It is approved for children and adolescents aged 8–17 with recently diagnosed Type 1 diabetes and for children as young as 1 year with stage 2 disease (multiple autoantibodies and early blood sugar changes).
However, experts are clear about teplizumab's limits. The drug slows the rate at which the body's own insulin-producing beta cells decline—an important first step—but it does not stop that decline entirely or allow most people to stop taking insulin. As one leading researcher put it: "It slows the rate of decline, which is a win. But it's winning a battle, not winning the war."
This recognition has prompted researchers to explore a new strategy: combining teplizumab or similar immune-modulating drugs with other therapies that work through different mechanisms. Early evidence from case reports and ongoing clinical trials suggests that this multi-drug approach may offer better long-term control of blood sugar and beta cell preservation than any single agent alone.
A Stage-Based Approach: Matching Treatment to Disease Timing
Research increasingly suggests that Type 1 diabetes should not be treated with a one-size-fits-all approach. Instead, the disease's stage—from presymptomatic autoimmunity to recent-onset to longstanding disease—shapes which treatments are most likely to work.
Early stages of Type 1 diabetes appear to offer a critical window of opportunity. At this point, the immune system's harmful response to beta cells may still be reversible, and enough functional beta cells remain to potentially preserve. Immune-modulating drugs like teplizumab fit this window well, as they aim to redirect or calm the autoimmune attack.
As the disease progresses and the immune system's destructive memory becomes more entrenched, fewer beta cells survive, and immune-modulating drugs alone become less effective. In these later stages, researchers believe new therapies—such as regenerative approaches to replace lost beta cells or protect transplanted cells—may eventually prove necessary. The combination of multiple strategies tailored to disease stage represents a more sophisticated path forward than current single-drug treatments.
The Emerging Role of the Microbiome
Beyond immune-modulating drugs, scientists are investigating how the trillions of bacteria living in our gut—the microbiome—influence Type 1 diabetes risk and progression. Animal studies have shown that changes in the microbiome can affect whether the immune system attacks beta cells, and human studies have linked microbiome composition to Type 1 diabetes development.
Researchers have also identified connections between viral infections and changes in islet autoimmunity, suggesting that microbial exposures in early childhood may shape diabetes risk. While the specific bacteria or viruses responsible remain unclear, this research opens a new frontier: therapies designed to modify or restore healthy microbiota as a way to prevent or slow Type 1 diabetes.
Integrating microbiome data with genetic, immune, and environmental information using advanced analytical methods may eventually help clinicians predict who will develop Type 1 diabetes and personalize prevention strategies.
Beyond Medication: Screening, Lifestyle, and Mental Health
While new drugs represent important progress, managing Type 1 diabetes risk involves more than medication. Screening for autoantibodies—immune markers that signal the disease is beginning—allows families to prepare and intervene early. This screening is particularly valuable in adolescents and teens, who often develop Type 1 diabetes.
Lifestyle factors also matter. Although no diet or exercise regimen can prevent Type 1 diabetes alone, certain nutritional choices and weight management strategies may help preserve insulin sensitivity and reduce metabolic strain. Education and practical support for families can help sustain these lifestyle adjustments.
Finally, receiving a diagnosis of pre-Type 1 diabetes or managing disease risk takes a psychological toll on teens and families. Counseling, cognitive-behavioral therapy, and peer support are recommended to address anxiety, family stress, and quality-of-life concerns. A comprehensive approach that honors both physical and mental health is essential.
The Path Forward
The approval of teplizumab marked a milestone: it is the first disease-modifying drug approved for Type 1 diabetes. Yet experts agree it is not the end of the story. Combining teplizumab with other agents targeting different pathways, matching treatments to disease stage, and investigating new mechanisms like microbiome modification represent the realistic next steps toward better outcomes.
For patients, parents, and caregivers, this means staying informed about emerging clinical trials, working closely with specialists who understand both medical and psychosocial aspects of Type 1 diabetes, and maintaining realistic hope. Progress is occurring, but it is incremental: slowing disease decline, not yet curing it. With continued research and a multi-faceted approach, the long-term goal of preserving beta cell function and reducing insulin dependence is becoming more plausible.
Evidence label
Origin: medscape.com (News report). Evidence: News report, corroborated with 3 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.
From Type1Cure
Related reading
More evidence-labeled coverage across the Type1Cure library.
- Research summaryCure & AdvancementsCell Replacement Therapy: A New Frontier in Type 1 Diabetes ResearchVideo report, corroborated with 5 indexed studies
- Research summaryCure & AdvancementsWhy Beta Cells Die in Type 1 Diabetes While Alpha Cells SurviveNews report, corroborated with 2 indexed studies
- Research summaryCure & AdvancementsEarly Trial Shows Some People with Type 1 Diabetes Can Reduce or Stop Insulin—Here's What We KnowNews report, corroborated with 3 indexed studies
- Research summaryCure & AdvancementsBeta Cell Therapy: Moving From Lab Promise to Real-World TreatmentVideo report, corroborated with 2 indexed studies
- Research summaryCure & AdvancementsUnderstanding the Eleodon Trial: What Early Results ShowVideo report — unverified, pending corroboration
- Research summaryCure & AdvancementsIslet Cell Therapies Advance: What You Need to KnowNews report, corroborated with 3 indexed studies